|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Two patients with BRAF-V600E mutant melanoma who had documented progression during treatment with dabrafenib/GSK1120212 and dabrafenib, respectively, were rechallenged with dabrafenib and vemurafenib after a treatment-free interval of 8 and 4 months during which further progression was documented.
|
22584957 |
2012 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The DDFI was significantly shorter in patients with BRAF(V600K/R) versus BRAF(V600E) melanoma in univariate and multivariate analyses.
|
24918823 |
2014 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
|
28475671 |
2017 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Sodium arsenite- or statin-induced apoptosis was independent of BRAF status (wild type versus V600E) in melanoma lines.
|
21910007 |
2011 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
PLX4032 induces potent cell cycle arrest, inhibits proliferation, and initiates apoptosis exclusively in V600E-positive cells in a variety of in vitro experimental systems; follow-up xenograft studies demonstrate extreme selectivity and efficacy against melanoma tumors bearing the V600E oncoproduct.
|
20973932 |
2010 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Coexistence of BRAF V600E mutation and EZH2 gain is rather prevalent in melanoma.
|
29202777 |
2017 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The disease-free interval from diagnosis of primary melanoma to first distant metastasis was shorter for patients with V600K compared with V600E melanoma (17.4 vs. 39.2 months, P = 0.048), with no difference in survival thereafter.
|
22535154 |
2012 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Thus, AURKB and WEE1 are targets and biomarkers of therapeutic efficacy, lying downstream of (V600E)B-RAF in melanomas.
|
23416158 |
2013 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Vemurafenib and dabrafenib are B-Raf<sup>V600E</sup> inhibitors that were approved for the treatment of melanomas bearing the V600E mutation.
|
30118796 |
2018 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We identified concurrent mutational inactivation of the PTEN and RB1 tumor suppressors as a mechanism for loss of BRAF/MEK dependence in melanomas harboring (V600E)BRAF mutations.
|
21725359 |
2012 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Vemurafenib and dabrafenib are both orally bioavailable small molecule agents that block mitogen activated protein kinase signalling in patients with melanoma and BRAF(V600E) mutation.
|
26056325 |
2015 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The T1799A (V600E) mutation was detected by sequencing in melanomas from 5 of 22 patients as well as in the positive control, a cutaneous melanoma cell line.
|
15277467 |
2004 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The frequency of KRAS mutations in the melanocytic aggregate (five of 18, 28%) was second to BRAF V600E, while in melanoma</span>, the frequency was also second to BRAF V600E but equalled that of NRAS2 (1 of 18, 6%).No NRAS1 mutations were observed.
|
18945298 |
2009 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The oncogenic mutation of BRAF(V600E) has been found in approximately 8% of all human cancers, including more than 60% of melanoma and 10% of colorectal cancers.
|
26810733 |
2016 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Compared to patients with BRAF wild-type melanomas, those with BRAF(V600E) mutants were significantly younger, had more nevi but fewer actinic keratoses, were more likely to report a family history of melanoma, and had tumors that were more likely to harbor neval remnants.
|
26807515 |
2016 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
|
16179870 |
2005 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this study, no association between BRAF-V600E mutation status of melanoma tumors and DDC after treatment with ipilimumab was detected.
|
22382362 |
2012 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Approximately 40-60% of melanomas from Caucasian populations carry activating mutations in the BRAF oncogene, with the most common being the p.Val600Glu (V600E) hotspot mutation in exon 15.
|
22614711 |
2012 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We demonstrate the use of INDRA and natural language to model three biological processes of increasing scope: (i) p53 dynamics in response to DNA damage, (ii) adaptive drug resistance in BRAF-V600E-mutant melanomas, and (iii) the RAS signaling pathway.
|
29175850 |
2017 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Fourty percent of all melanomas harbor a mutation in the signaling adaptor BRAF (V600E) that results in ERK hyperactivity as an oncogenic driver.
|
29983861 |
2018 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It.
|
27337967 |
2017 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Additionally, activation of FGFR3 sufficiently reactivated Ras/MAPK signaling and conferred resistance to vemurafenib in the parental B-RAF V600E melanoma cells.
|
22730329 |
2012 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We studied global gene expression in three melanoma cell lines with the most common and potent V600E mutation in the B-RAF gene-four cell lines with a common Q61R mutation in the N-RAS gene and three cell lines with no mutations using human HG-U133A 2.0 micro-arrays with 22 277 transcripts.
|
15760917 |
2005 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Selective inhibition of BRAF(V600E) by PLX4720 treatment of melanoma-bearing mice resulted in a strong decrease of tumor outgrowth.
|
22796458 |
2012 |
|
rs121913377
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Activating mutations in the BRAF serine/threonine kinase are found in more than 70% of human melanomas, >90% of which are BRAF(V600E).
|
22361686 |
2012 |